NeurogesX, Inc. (NASDAQ:NGSX)

CAPS Rating: 1 out of 5

A biopharmaceutical company, which focused on developing and commercializing novel pain management therapies.

Recs

0
Player Avatar Momentum21 (94.77) Submitted: 1/31/2012 10:55:48 AM : Underperform Start Price: $1.05 NGSX Score: +43.69

These guys have some issues and the upcoming "catalyst" seems to favor a large haircut.

Report this Post Reply

Featured Broker Partners


Advertisement